Contacts

Scientific Advisory Board

Prof. Claudio Bordignon
Chairman of MolMed's Board of Directors, Chairman of the SAB

Prof. Carl-Henrik Heldin
Branch Director of the Ludwig Institute for Cancer Research in Uppsala - Sweden, Professor in Molecular Cell Biology at Uppsala University

Prof. Robert Kerbel
Professor in the Departments of Medical Biophysic and of Laboratory Medicine & Pathobiology at the University of Toronto - Canada

Jean-Paul Prieels PhD
Advisor at GSK Vaccines and Chairman of the Board at ImmuneHealth

Prof. Alberto Sobrero
Director of the Medical Oncology Unit at S. Martino Hospital in Genova - Italy

- - -

Prof. Claudio Bordignon
Chairman of MolMed's Board of Directors, Chairman of the SAB

Claudio Bordignon, MolMed’s founder, has an established international reputation as a pioneer in gene and cell therapy, and is widely known for the clinical validation of several successful gene therapy protocols for both genetic and acquired disorders, including leukaemias ans other malignancies. He is the author of more than 150 publications and inventor of several patents, that represent crucial components of the company’s core technologies. He is Professor of Haematology at the University Vita-Salute San Raffaele Medical School, and Director of the Clinical Training Program in Haematology. In 2005, he was appointed by the EU Commission as one of the 22 eminent members of the Scientific Council of the European Research Council.
He served as Scientific Director of the San Raffaele Scientific Institute (1998-2006) and held positions as Director of Haematology, Head of the Gene Therapy and Bone Marrow Transplantation Program. Claudio Bordignon received his MD from the School of Medicine of the University of Milan, and completed his medical and science training during eight years spent in several of the most prestigious U.S. institutions, including four years at Memorial Sloan Kettering Cancer Center (New York).

Prof. Carl-Henrik Heldin
Branch Director of the Ludwig Institute for Cancer Research in Uppsala - Sweden, and professor in Molecular Cell Biology at Uppsala University

Carl-Henrik Heldin is since 1986 the Branch Director of the Ludwig Institute for Cancer Research in Uppsala - Sweden, and since 1992 Professor in Molecular Cell Biology at Uppsala University.
His research interest is related to the mechanisms of signal transduction by growth regulatory factors, as well as their normal function and role in disease, and focused on exploring the possible clinical utility of signal transduction antagonists.
Carl-Henrik Heldin is currently on the Board of the European Research Council and the Swedish Research Council, and serves as Senior Editor for Cancer Research and Associate Editor for Molecular Biology of the Cell, Genes to Cells and Growth Factors. He is a member of the European Molecular Biology Organisation, the Royal Swedish Academy of Sciences and Academia Europea. He serves and has served on the Scientific Advisory Boards for several companies and academic institutions, including the German cancer Center, Heidelberg, Max Planck Institute for Biochemistry, Martinsried, European Institute for Oncology, Milan, and European Molecular Biology Laboratory, Heidelberg.

Prof. Robert Kerbel
Professor in the Departments of Medical Biophysic and of Laboratory Medicine & Pathobiology at the University of Toronto - Canada

Robert Kerbel is Senior Scientist in the Molecular and Cellular Biology Research Program at the Sunnybrook Health Sciences Centre in Toronto - Canada, Professor in the Departments of Medical Biophysic and of Laboratory Medicine & Pathobiology at the University of Toronto, and Canada Research Chair in Tumour Biology, Angiogenesis and Antiangiogenic Therapy. He has worked for over 30 years in tumour biology research; since 1990, the main focus of his research has been to understand the basis of tumour angiogenesis, and the design of new therapeutic strategies for advanced metastatic disease based on vascular targeting and inhibition of tumor angiogenesis. His most noteworthy contributions include pioneering the concept and application of low-dose metronomic chemotherapy, the development of biomarker strategies for antiangiogenic drugs, elucidating mechanism of VEGF-pathway targeting drugs, uncovering the role of oncogenes in the tumour angiogenic switch, and the development of new models of advanced metastatic disease in mice. His work is highly translational, with direct impact on the start of several clinical trials around the world. Robert Kerbel is author of over 330 papers. He has served on the editorial boards of numerous journals, including Cancer Research, Molecular Cancer Research, Clinical Cancer Research, American Journal of Pathology, Neoplasia, Angiogenesis, and was Editor-in-Chief of Cancer & Metastasis Reviews from 1991 to 2000. He is a member of numerous advisory boards in both academia and industry.

Jean-Paul Prieels PhD
Advisor at GSK Vaccines and Chairman of the Board at ImmuneHealth

Jean-Paul Prieels is Advisor at GSK Vaccines and Chairman of the Board at ImmuneHealth. He started his distinguished career at SmithKline Beecham Biologicals (now GlaxoSmithKline Vaccines) in 1987, where he held various executive positions in the R&D department, including Member of the Board from 1999, and the position of Senior Vice President Research & Development from 2006 until 2011. He is currently member of the Board of Directors and/or of the Scientific Advisory Board of a number of biotech companies and research institutions with a particular focus on immunotherapy and cell therapy.

Prof. Alberto Sobrero
Director of the Medical Oncology Unit at S. Martino Hospital in Genova - Italy

Alberto Sobrero is Head of the Medical Oncology Unit at Ospedale San Martino in Genova - Italy since 2001. Before this, he was Associate Professor in Medical Oncology at the University of Florence and Udine - Italy.
His main research interests include chemotherapy, targeted agents in gastrointestinal cancer and design of clinical trials.
Professor Sobrero is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the European Society for Medical Oncology (ESMO), and several Italian scientific societies. From 2002 to 2006, Professor Sobrero has been the Chairman of the Protocol Review Committee of the European Organisation for Research and Treatment of Cancer (EORTC). He has also served on the editorial board of the Journal of Clinical Oncology 2003-2006 and is presently member of the Scientific Committee of ASCO as well as the Educational Committee of the ESMO.

 

MolMed S.p.A. Via Olgettina, 58 - 20132 Milano, Italy | Phone +39 0221277.1 - Fax +39 02 21277.325 | info@molmed.com - www.molmed.com
Share capital € 20,312,682.30 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159